|
|
|
| project no |
acronym and title |
duration |
| H2020 - 952792
|
2D-EPL - Graphene Flagship 2D Experimental Pilot Line |
2020-2024 |
| H2020 - 696656
|
GrapheneCore1 - Graphene-based disruptive technologies |
2016-2018 |
| H2020 - 785219
|
GrapheneCore2 - Graphene Flagship Core Project 2 |
2018-2020 |
| H2020 - 881603
|
GrapheneCore3 - Graphene Flagship Core Project 3 |
2020-2023 |
| H2020 - 965381
|
TIMESPAN - Management of chronic cardiometabolic disease and treatment discontinuity in adult ADHD patients |
2021-2026 |
| FP7 - 202162
|
LACTOBODY - Production and delivery of antibody fragments against gastrointestinal pathogens by lactobacilli |
2008-2012 |
| FP7 - 223091
|
SEYLE - Saving and Empowering Young Lives in Europe: Promote health through prevention of risk-taking and self-destructive behaviors |
2009-2011 |
| FP7 - 222720
|
TORNADO - Molecular Targets Open for Regulation by the gut flora – New Avenues for improved Diet to Optimize European health |
2009-2013 |
| FP7 - 241542
|
WE-STAY - Work Toghether to Stop Truancy Among Youth |
2010-2013 |
| FP6 - 508912
|
BIODEFENSE - Rapid induction of passive immunity against weapons of bioterrorism using transformed GRAS (generally regarded as safe) microorganisms |
2004-2007 |
| FP6 - 502983
|
MUTP53 - Mutant p53 as target for improved cancer treatment |
2004-2009 |
| FP5 - 51442
|
FUNCTION OF P75NTR - Novel Mechanisms of Cell Communication in the Nervous System: Physiology and Function of the P75 Neurotrophin Receptor |
2000-2003 |
| FP5 - 58964
|
RECEPTOR HETERODIMER - Heteromerization of adenosine and dopamine receptor subtypes. Relevance for neuronal integration in normal and pathological states |
2001-2004 |
|
|
